GRALV

GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.